Relay Therapeutics Inc. (NASDAQ:RLAY) finished Wednesday with an addition of $4.99 to close at $32.76, an upside of 17.97 percent. An average of 3,028,720 shares of common stock have been traded in the last five days. There was a gain of $3.26 in the past week. The last 20 days have seen an average of 1,275,120 shares traded, while the 50-day average volume stands at 875,300.
RLAY stock has decreased by -7.48% in the last month. The company shares reached their 1-month lowest point of $25.72 on 10/08/21. With the stock rallying to its 52-week high on 01/20/21, shares of the company touched a low of $25.72 and a high of $64.37 in 52 weeks. In spite of this, the price is down -49.11% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
17 days have passed since Relay Therapeutics Inc. (RLAY) last reported insider trading activity. Catinazzo Thomas, who is Senior Vice President, Finance, most recently acquired $293 shares at $36.87 per share on Sep 27. In this transaction, the insider spent $10,803. See Remarks, Bergstrom Donald A, disposed of 646 shares at a price of $36.87 on Sep 27. The insider now owns more than $23,818 worth of shares. Prior to that, General Counsel Adams Brian went on to Sale 293 shares at $36.87 each on Sep 27. An amount of $10,803 was transacted.
Relay Therapeutics Inc. (RLAY) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 33.18, the price-to-book (PB) ratio at 4.87.
The quick ratio of Relay Therapeutics Inc. for the three months ended June 29 was 26.80, and the current ratio was 26.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Relay Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -63.21%. Its gross profit as reported stood at $138.45 million compared to revenue of $82.65 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Relay Therapeutics Inc.’s return on assets was -54.50%. For the broader industry, ROE averaged -68.79 over the past year.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $0.84 million in the quarter, while revenues of $0.95 million were grew 100.0%. The analyst consensus anticipated Relay Therapeutics Inc.’s latest quarter earnings to come in at -$0.46 per share, but it turned out to be -$2.1, a -356.50% surprise. For the quarter, EBITDA amounted to -$192.07 million. Shareholders own equity worth $92.69 million.
From a technical analysis perspective, let’s take a brief look at Relay Therapeutics Inc. (RLAY) price momentum. RSI 9-day as of the close on 13 October was 55.44%, suggesting the stock is Neutral, with historical volatility in this time frame at 127.19%.
As of today, RLAY’s price is $28.80 +11.05% or $3.26 from its 5-day moving average. RLAY is currently trading -11.29% lower than its 20-day SMA and +8.87% higher than its 100-day SMA. However, the stock’s current price level is +2.18% above the SMA50 and -27.35% below the SMA200.
The stochastic %K and %D were 33.98% and 24.13%, respectively, and the average true range (ATR) was 3.14. With the 14-day stochastic at 56.64% and the average true range at 2.74, the RSI (14) stands at 52.06%. The stock has reached 0.78 on the 9-day MACD Oscillator while the 14-day reading was at -1.38.
BofA Securities launched coverage on Relay Therapeutics Inc. (NASDAQ: RLAY) in its analyst report released on July 21, 2021. The firm assigned the stock a a Buy rating.The consensus rating for Relay Therapeutics Inc. (RLAY) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell RLAY, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is RLAY’s price target for the next 12 months?
Analysts predict a range of price targets between $50.00 and $59.00, with a median target of $53.00. Taking a look at these predictions, the average price target given by analysts for Relay Therapeutics Inc. (RLAY) stock is $53.83.